Market Cap 105.66M
Revenue (ttm) 0.00
Net Income (ttm) -26.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 420,000
Avg Vol 340,906
Day's Range N/A - N/A
Shares Out 91.88M
Stochastic %K 67%
Beta 1.94
Analysts Strong Sell
Price Target $5.33

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 225 7416
Address:
2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States
Jl37
Jl37 Nov. 12 at 2:58 PM
$CNTX I’m ok with the low volume with nobody selling!
0 · Reply
Jl37
Jl37 Nov. 10 at 2:58 PM
0 · Reply
dudereally
dudereally Nov. 9 at 4:22 PM
$BCAB $CNTX I don’t see anything about BCAB It appears to all just be drugs that they’re working on.
3 · Reply
BiotechValues
BiotechValues Nov. 9 at 12:11 AM
$BCAB $CNTX PR yesterday about BCAB's program. Can access the poster on their site: https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-highlights-ct-95-and-ct-202-programs-2025
0 · Reply
LabPsycho
LabPsycho Nov. 8 at 3:17 PM
$CNTX @BiotechValues Thanks for your post - I was wondering how that partnership was going. Do you know status of BCAB delisting / extension notices if any?
1 · Reply
BiotechValues
BiotechValues Nov. 6 at 2:03 PM
$BCAB triggered a $2M milestone in October from $CNTX partnership. Anything helps as we await the ph3 deal due by end of year. From $CNTX 10q below. On track to initiate ph1 study of $BCAB's Nectin-4 program in q2 2026.
1 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:22 PM
D. Boral Capital has updated their rating for Context Therapeutics ( $CNTX ) to Buy with a price target of 9.
0 · Reply
Jl37
Jl37 Nov. 6 at 1:06 PM
$CNTX maybe good news with earnings…
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 11:51 AM
HC Wainwright & Co. updates rating for Context Therapeutics ( $CNTX ) to Buy, target set at 4 → 5.
0 · Reply
d_risk
d_risk Nov. 5 at 9:16 PM
$CNTX - Context Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors CNTX flags new risks of costly patent litigation, expanded U.S. tariff threats now targeting pharmaceuticals, and regulatory uncertainty from possible FDA budget cuts, HHS leadership changes, and a new government efficiency commission. #Pharmaceuticals #U.S.Tariffs #FDABudgetCuts #RegulatoryUncertainty #PatentLitigation 🟢 Added 🟠 Removed https://d-risk.ai/CNTX/10-Q/2025-11-05
0 · Reply
Latest News on CNTX
Context Therapeutics: Undervalued Cancer Fighter

Jun 10, 2025, 7:10 AM EDT - 5 months ago

Context Therapeutics: Undervalued Cancer Fighter


Jl37
Jl37 Nov. 12 at 2:58 PM
$CNTX I’m ok with the low volume with nobody selling!
0 · Reply
Jl37
Jl37 Nov. 10 at 2:58 PM
0 · Reply
dudereally
dudereally Nov. 9 at 4:22 PM
$BCAB $CNTX I don’t see anything about BCAB It appears to all just be drugs that they’re working on.
3 · Reply
BiotechValues
BiotechValues Nov. 9 at 12:11 AM
$BCAB $CNTX PR yesterday about BCAB's program. Can access the poster on their site: https://ir.contexttherapeutics.com/news-releases/news-release-details/context-therapeutics-highlights-ct-95-and-ct-202-programs-2025
0 · Reply
LabPsycho
LabPsycho Nov. 8 at 3:17 PM
$CNTX @BiotechValues Thanks for your post - I was wondering how that partnership was going. Do you know status of BCAB delisting / extension notices if any?
1 · Reply
BiotechValues
BiotechValues Nov. 6 at 2:03 PM
$BCAB triggered a $2M milestone in October from $CNTX partnership. Anything helps as we await the ph3 deal due by end of year. From $CNTX 10q below. On track to initiate ph1 study of $BCAB's Nectin-4 program in q2 2026.
1 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:22 PM
D. Boral Capital has updated their rating for Context Therapeutics ( $CNTX ) to Buy with a price target of 9.
0 · Reply
Jl37
Jl37 Nov. 6 at 1:06 PM
$CNTX maybe good news with earnings…
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 11:51 AM
HC Wainwright & Co. updates rating for Context Therapeutics ( $CNTX ) to Buy, target set at 4 → 5.
0 · Reply
d_risk
d_risk Nov. 5 at 9:16 PM
$CNTX - Context Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors CNTX flags new risks of costly patent litigation, expanded U.S. tariff threats now targeting pharmaceuticals, and regulatory uncertainty from possible FDA budget cuts, HHS leadership changes, and a new government efficiency commission. #Pharmaceuticals #U.S.Tariffs #FDABudgetCuts #RegulatoryUncertainty #PatentLitigation 🟢 Added 🟠 Removed https://d-risk.ai/CNTX/10-Q/2025-11-05
0 · Reply
Jl37
Jl37 Nov. 4 at 2:54 PM
$CNTX losing my as now.
1 · Reply
VA_24
VA_24 Oct. 31 at 2:51 PM
$CNTX They diluted SMH With all the cash they still too advantage of the spike!! It explains the price action Shares outstanding before compliance were 75 million and now it’s 89
0 · Reply
Jl37
Jl37 Oct. 31 at 1:55 PM
$CNTX well shit!
0 · Reply
Rocb
Rocb Oct. 29 at 10:48 PM
$CNTX must have something positive to say next weekend or else why would they be there
1 · Reply
Jl37
Jl37 Oct. 28 at 4:52 PM
$CNTX is this going below a dollar again?
1 · Reply
Jl37
Jl37 Oct. 27 at 1:42 PM
0 · Reply
SpencerF
SpencerF Oct. 22 at 7:16 PM
$CNTX hope we didn’t miss last chance to dump
0 · Reply
bobmccusker
bobmccusker Oct. 22 at 1:25 PM
$CNTX https://www.tipranks.com/news/company-announcements/context-therapeutics-regains-nasdaq-compliance
1 · Reply
Jl37
Jl37 Oct. 21 at 5:03 PM
$CNTX terrible
1 · Reply
Jl37
Jl37 Oct. 20 at 4:52 PM
$CNTX started so well.
0 · Reply
TheJunksCalls
TheJunksCalls Oct. 20 at 1:20 PM
$KUKE <~~ Rinse & Repeat Play Every Year✅ KUKE went straight up everyday before market closed for weeks straight. I’m talking 10%+ everytime starting at 3:50 ET for the last couple years. After the loading was done it went up 200%+. Once it regains compliance it’s back in the dumps before they run it up again. This will run over $1+ any day/week. Process doesn’t chang here. $BULL $REI $ICCM $CNTX Long Plays 👊🏻
1 · Reply
LabPsycho
LabPsycho Oct. 20 at 1:16 PM
$BCAB @3SSA By my estimations, I think BCAB presently likely has almost near zero cash remaining. And what about reverse split / compliance - is this a concern? Their data looks encouraging but I dont know how they can stay afloat without massive dilution and any potential partner with $$$ knows BCAB needs them more than they need BCAB. To me, the most likely partnership or (gasp) [reverse] merger would be with $CNTX, which of course would really stick it to current investors of either company - its the Wall Street way.
1 · Reply